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Low density lipoprotein (LDL) doped with the anticancer mixture of hematoporphyrin derivatives Photo- 
frin II (P2) competes with native LDL for binding to fibroblast receptors, despite a slight increase in the 
negative net charge related to the presence of acidic residues of porphyrins. P2 delivery to fibroblasts can 
be achieved by LDL, HDL3 or albumin doped with P2 (LDL-P2, HDL-P2 or A-P2, respectively). P2 delive- 
ry to cells assessed by fluorescence measurement, is much more efficient, at low protein concentrations (1 t& 
20 pg/ml) by LDL-P2 than by HDL-P2 or A-P2. Moreover, P2 delivery to cells by LDL-P2 as a function 
of protein concentration is a saturable process, whereas P2 delivery by HDL-P2 or A-P2 is a linear process. 
Finally, reduction of the LDL-receptor number by preincubation of fibroblasts in medium supplemented 
with lipoproteins results in a decrease of P2 delivery by LDL-P2. These results suggest a special role of 
the LDL-receptor pathway in P2 delivery to cells and could be of interest in cancer phototherapy by por- 
phyrins. 
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1. INTRODUCTION 
Protoporphyrin and hematoporphyrin have 
been demonstrated to bind to albumin and 
lipoproteins [ 1,2], mainly low density lipoproteins 
(LDL) and high density lipoproteins (HDL). The 
LDL uptake by cells is achieved by receptor- 
mediated endocytosis, which results in LDL- 
component delivery to the lysosomal compartment 
[3,4]. Several authors pointed out an increase in 
LDL catabolism by transformed cells [5-71, and it 
has thus been suggested to use LDL as a carrier for 
lipophilic antitumoral drugs [8,9]. Hematopor- 
phyrin derivatives have been proposed for tumor 
diagnosis and phototherapy [ 10,111. Among them, 
photofrin II (P2) is a recently developed mixture 
which includes the main active component [ 121. 
Due to poor intrinsic solubility in water, it forms 
high molecular mass aggregates in aqueous solu- 
tions. It should therefore exhibit a rather good af- 
finity for lipophilic environments encountered in 
LDL. Since data on its pharmacokinetics using 
lipoproteins as carriers are not yet available, we in- 
vestigated the interaction of P2 with LDL and its 
consequences on LDL binding to human 
fibroblasts by competition with native LDL. We 
also compared the delivery of P2 to cells by various 
serum proteins doped with P2: albumin (A-P2), 
LDL (LDL-P2), and HDL3 (HDL-P2). 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Human foetal lung fibroblasts (strain MRCS) 
were purchased from Biomerieux (France), and 
maintained in Ham FlO medium (Flow) sup- 
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plemented with 10% foetal calf serum (Gibco), in 
25 cm’ Falcon flasks, at 37”C, in a 5% CO2 
humidified atmosphere. 
2.2. Preparation of LDL and HDL3 
HDL3 and LDL were prepared from normal 
human serum by the method of Have1 et al. [13]. 
LDL and HDL3 were the 1.024-1.050 and the 
1.125-l .21 fractions, respectively. 
2.3. Labeling of LDL 
LDL was labeled according to Bilheimer et al. 
[14], using “‘1-Na (Amersham, 13-17 mCi/,ug). 
The specific radioactivity was about 
250-350 cpm/ng of LDL protein. Protein deter- 
mination was done according to Lowry et al. [15]. 
2.4. Loading albumin, HDL3 and LDL with P2 
P2 (Photofrin Medical Inc., Raritan, NJ) was 
added as concentrated (2.5 mg/ml) aqueous solu- 
tion to diluted proteins, to achieve the same con- 
centration of P2 in the incubation medium 
(13.7 pg/ml). The protein concentrations were 
such that their ratio corresponded to their ratio in 
plasma: thus, the solution to be doped contained 
0.2 mg/ml LDL or HDL3, and 5 mg/ml bovine 
serum albumin (Sigma). Proteins were diluted in 
0.1 M Tris buffer, 0.15 M NaCl, pH 7.4. These 
conditions have been chosen after preliminary ex- 
periments in order to obtain measurable 
fluorescence intensities. P2-loaded proteins were 
prepared just before use. 
2.5. Competition between LDL-P2 and iodinated 
LDL 
Fibroblasts were seeded at 25000/cm2 in 35 mm 
Petri dishes, and grown for 48 h in Ham FlO 
medium supplemented with 10% foetal calf serum. 
The medium was then replaced by fresh 
lipoprotein-deficient medium (Ham FlO + 2% 
Ultroser G, IBF), for maximal receptor expression. 
After 24 h, cells were washed and incubated for 
1 h at 4°C with lOpg/ml ‘251-LDL in the absence 
or presence of unlabeled native LDL or LDL-P2 at 
various concentrations, in 0.1 M Tris10.15 M 
NaCl buffer, pH 7.4. After incubation, cells were 
washed 4 times with the same buffer, harvested 
with rubber policemen, centrifuged, and the 
radioactivity in the pellet measured using a 
Packard gamma counter. Protein determination 
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was done on the same sample, and results are ex- 
pressed in % of control (12’1-LDL alone). 
2.6. P2 delivery to cells by A-P2, HDL-P2 and 
LDL-P2 
After a 24 h preincubation in Ham FlO 
medium + 2% Ultroser G, cells were washed, and 
then incubated for 1 h at 37°C with PZloaded pro- 
teins at various concentrations, in 1 ml of 0.1 M 
Tris buffer/O.15 M NaCI, pH 7.4. In experiments 
designed for the study of the effect of serum 
lipoproteins on P2 delivery to cells, cultures were 
preincubated for 24 h either in Ham FlO medium 
supplemented with 10% foetal calf serum, or in 
Ham FlO medium supplemented with 2% Ultroser 
G. After incubation with PZdoped proteins, cells 
were washed 4 times and harvested with rubber 
policemen. After centrifugation, the fluorescence 
of the pellet was measured with a Perkin Elmer 
LS5 spectrofluorometer. The excitation and emis- 
sion wavelengths were 405 and 632 nm, respective- 
ly. Results are expressed in arbitrary units 
(fluorescence intensity/pg of cell protein). 
3. RESULTS AND DISCUSSION 
As seen in fig.1 (inset), aqueous P2 (1.8 pug/ml) 
exhibited a fluorescence peak at 613 nm. Addition 
of LDL to the solution increased the fluorescence 
intensity, and induced a red shift of the emission 
maximum to 627 nm. Fig.1 also displays the in- 
crease in fluorescence intensity of P2 as a function 
of LDL concentration. The fluorescence intensity 
increased with LDL concentration, reaching a 
plateau at 0.38 mg/ml. This can be interpreted as 
the result of the incorporation and monomerisa- 
tion of the porphyrin aggregates into the LDL. 
From the intercept between the plateau level and 
the initial slope of the fluorescence intensity graph, 
it is evaluated that 14Opg LDL (protein weight) 
can incorporate up to 1.8 gg P2, e.g. 1 LDL 
molecule for about 130 porphyrin rings (600 Da = 
average molecular mass of a porphyrin ring). 
Under the same conditions [2], one LDL molecule 
can only bind 50 molecules of the closely related 
protoporphyrin, responsible for skin photosen- 
sitivity in porphyria patients. 
Fig.2 displays the electrophoretic profile of 
native LDL and LDL-P2. The cationic mobility of 
LDL-P2 is slightly increased as compared to native 
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Fig. 1. Fluorescence intensity of a 1.8 pg/ml solution of Photofrin II (excitation and emission wavelengths: 500 and 
628 nm, respectively) as a function of the LDL concentration in saline phosphate buffer. Inset: emission fluorescence 
spectrum of 1.8 pg/ml Photofrin II in the absence of LDL (---) and in the presence of 0.38 mg/ml LDL (-). 
LDL (+ 3 mm). This increase in the negative net 
charge of LDL is probably due to the presence of 
acidic (acetic, propionic) residues of the por- 
phyrin. 
It was of interest o investigate if this increase in 
the negative charge of the LDL could modify the 
interaction of the lipoprotein with its specific 
receptor at the cell surface, since chemical 
modifications of LDL such as acetylation have 
been reported to strongly decrease LDL binding to 
fibroblasts [16,17]. Fig.3 shows that there was no 
significant difference in the ability of native or 
Pa-doped LDL to compete with ‘251-LDL. 
The delivery of P2 to MRCS fibroblasts by 
LDL-P2, HDL-P2 and A-P2 as a function of the 
carrier protein concentration is shown in fig.4. 
Clearly a plateau was obtained for about 
30-40 pg/ml of LDL-P2, whereas the fluorescence 
increased quite linearly with carrier protein con- 
centration for HDL-P2 or A-P2. Furthermore, the 
fluorescence recovered in fibroblasts was markedly 
higher from LDL-P2 than from HDL-P2 or A-P2, 
in the range of 5-25 pg/ml. At 10 /cg/ml, LDL-P2 
was about 3-fold more efficient than HDL-P2. The 
efficiency of HDL-P2 was comparable to that of 
LDL-P2 only at very high concentrations (above 
Fig.2. Agarose gel electrophoresis of native LDL and 
LDL-P2 (Universal Electrophoresis Film Agarose 19’0, 
Corning; staining: Red Oil 0). LDL-P2 exhibits an 
increased cationic mobility (about + 3 mm as compared 
to native LDL). 
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Fig.3. Competition between 12’I-LDL and native LDL 
(‘I) or P2-doped LDL (e). Cells were preincubated for 
24 h in Ham FlO medium supplemented with 2% 
Ultroser G, washed, and LDL binding measured as 
described in section 2 with iZ51-LDL (lOpg/ml) in the 
absence or presence of native or P2-doped LDL. Results 
are expressed in (70 of control (“‘I-LDL alone). 100%: 
118 + 15 ng LDL bound/mg of cell protein; mean of 3 
experimental values. 
10 20 10 70 LDL.1 
Fig.4. P2 delivery to MRCS fibroblasts by LDL-P2, 
HDL-P2 or A-P2. Cells were preincubated for 24 h in 
Ham FlO medium supplemented with 2% Ultroser G, 
for maximal expression of LDL-receptors, then washed, 
and incubated for 1 h at 37°C in 0.1 M Tris/O.lS M 
NaCI, pH 7.4, buffer with P2-loaded proteins at various 
concentrations. P2 delivery to cells was assessed by 
fluorescence measurement. Results are expressed in 
arbitrary units (fluorescence intensity/mg cell protein). 
Lower scale: LDL-P2 (0) or HDL-P2 (A). Upper scale: 
A-P2 (w). Mean of 3 experiments. 
50pg/ml). A-P2 was much less effective, as 
lO,ug/ml of LDL-P2 gave about a 5-fold higher 
fluorescence than 250 pg/ml of A-P2. 
The influence of the preincubation of cells in the 
absence or presence of lipoproteins has also been 
studied (fig.5). The fluorescence recovered from 
LDL-P2 in fibroblasts preincubated for 24 h in a 
lipoprotein-deficient medium was about two-fold 
higher than that of fibroblasts preincubated in 
medium supplemented with 10% foetal calf serum. 
From these results, it can be concluded that: 
(i) P2 binds to LDL, probably by insertion into 
the external eaflet of the lipoprotein, as suggested 
by the increase in negative net charge of LDL-P2 
as compared to native LDL. It is worthy of note 
that the binding of P2 to LDL does not significant- 
ly alter the ability of LDL to be recognized by its 
specific receptor at the cell surface, despite this 
slight increase in the negative net charge of the 
lipoprotein. 
(ii) P2 delivery to fibroblasts from LDL seems to 
be mainly achieved by the receptor pathway, as 
suggested by studies of the carrier-protein concen- 
tration and time dependency of the phenomenon, 
as well as by the study of the influence of prein- 
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Fig.5. Effect of LDL-receptor expression on P2 delivery 
to MRCS fibroblasts. Cells were preincubated for 24 h 
either in Ham FlO medium supplemented with 2% 
Ultroser G (o), for maximal expression of LDL 
receptors, or in Ham F10 medium supplemented with 
10% foetal calf serum (0). P2 delivery to cells was 
assessed by fluorescence measurement. Results are 
expressed in arbitrary units (fluorescence intensity/mg 
cell protein). Mean of 3 experiments. 
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cubation in a medium devoid of lipoproteins. In 
this latter condition, cells exhibited an increased 
number of LDL receptors, as demonstrated by 
Goldstein and Brown [3]. Thus, the rise in LDL-P2 
uptake when receptor expression is maximum sup- 
ports the hypothesis of a role of the receptor 
pathway. However, it must be considered that a 
24 h preincubation of cells in whole medium 
decreased P2 delivery only 2-fold, whereas in the 
same conditions the LDL-receptor number, 
measured with 1251-LDL, was about 4-5-fold 
reduced. This suggests that, besides the LDL- 
receptor pathway, P2 may also enter by non- 
specific mechanisms. A similar observation has 
been recently reported for the delivery of the an- 
thracyclin derivative AD-32 to white blood cells by 
LDL [9]. 
(iii) From the three studied P2 carriers, LDL ap- 
pears to be the most efficient, especially at low 
concentrations. 
Thus, the LDL-receptor pathway is possibly in- 
volved in P2 delivery to cells. This is of interest in 
view of the fact that several reports pointed out a 
significant increase in LDL catabolism by the 
receptor pathway in transformed cells as compared 
to their normal counterparts [5-71. The use of 
LDL as a carrier for other lipophilic antimitotic 
drugs has been previously suggested, taking advan- 
tage of this increased LDL uptake by tumor cells, 
in order to improve the selectivity of drugs towards 
tumor cells [18]. 
It is also of interest o consider that P2 probably 
reaches the lysosomal compartment by the LDL- 
receptor pathway, whereas it can be suspected that 
it is widely distributed among cellular membranes 
when delivered by albumin or HDL. Experiments 
are now undertaken to specify the intracellular 
distribution of P2 delivered by LDL, HDL or 
albumin by fluorescence microscopy. If it is con- 
firmed that P2 rapidly reaches lysosomes after 
delivery by LDL-P2, this may be interesting for the 
strategy of cancer phototherapy. Indeed, irradia- 
tion of porphyrins induces the formation of very 
active oxygen species such as singlet oxygen [ 191. 
This could lead to disruption of lysosomes and 
release of lysosomal enzymes in the cytosol, with 
subsequent cytolysis. 
Moreover, generation of singlet oxygen by por- 
phyrins can induce oxidation of unsaturated LDL 
lipids. It is well established that oxidation products 
of cholesterol such as 25-hydroxycholesterol 
strongly inhibit endogenous cholesterol biosyn- 
thesis [20]. It is possible that this is also true for 
other lipid oxidation products, which can con- 
tribute to decrease tumor cell proliferation. In ad- 
dition, oxidized LDL has been reported to be 
cytotoxic towards fibroblasts [21,22]. It thus may 
be suggested that the LDL-receptor pathway can 
enhance tumor cell killing by porphyrin derivatives 
through delayed secondary reactions induced by 
decomposition of photoperoxides of LDL lipids. 
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